Viral Infection of HSPC Impacts Hematopoiesis

Recruiting now

Conditions studied: HIV-1, SARS-CoV-2

In brief

We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis.

Key facts

Study ID

NCT06458504

Run by

Assistance Publique - Hôpitaux de Paris

People needed

45

Starts

2024-10-25

Expected to finish

2026-03-01

Last updated by the study team

2025-03-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV patients :
• HIV-positive patients with a negative or positive viral load.
• managed at Ambroise Paré Hospital.
• patients with a bone marrow biopsy or myelogram performed as part of their care.
• Healthy subjects without HIV - patients with a BM biopsy or myelogram performed as part of their care for a suspected hematological pathology.
• Management at Ambroise Paré Hospital.

Where it is running

• Hematology and interne medicine department, Ambroise Paré hospital - APHP — Boulogne-Billancourt, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.